IDEAYA Biosciences宣布获得Ide034的IND批准,成为首个针对多种实体肿瘤类型的双特异性B7h3/Ptk7 Top1抗体药物

美股速递
Dec 01, 2025

IDEAYA Biosciences宣布获得Ide034的IND批准,这是一款潜在的首个针对多种实体肿瘤类型的双特异性B7h3/Ptk7 Top1抗体药物。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10